Compare HTLD & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | SLDB |
|---|---|---|
| Founded | 1978 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.1M | 759.8M |
| IPO Year | 1995 | 2017 |
| Metric | HTLD | SLDB |
|---|---|---|
| Price | $14.28 | $6.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $11.50 | ★ $16.36 |
| AVG Volume (30 Days) | 505.5K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,709,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.00 | $2.73 |
| 52 Week High | $14.27 | $8.87 |
| Indicator | HTLD | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 40.76 |
| Support Level | $12.23 | $5.16 |
| Resistance Level | N/A | $6.97 |
| Average True Range (ATR) | 0.52 | 0.51 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 100.00 | 25.91 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.